Business news

MINSK, 7 August (BelTA) – Belarusian specialists will be able to improve their skills at innovative Indian pharmaceutical enterprises. The statement was made by Yusuf Khwaja Hamied, Non-Executive Chairman of the Indian company Cipla Limited, before he met with Chairman of the Council of the Republic of the National Assembly of Belarus Mikhail Myasnikovich on 7 August, BelTA has learned. Mikhail Myasnikovich is in charge of overseeing cooperation with India.

Yusuf Khwaja Hamied outlined cooperation development plans. There are plans to allow Belarusian technical specialists to get trained in India. According to the source, Belarusian specialists will be able to improve their skills at cutting-edge enterprises that make pharmaceutical products. Besides, the meeting in the Council of the Republic of the National Assembly of Belarus also touched upon prospects of establishing an R&D center in Belarus and a manufacturing site after that.

On 6 August Yusuf Khwaja Hamied took part in the ceremony to open a landscape complex in honor of the construction of the pharmaceutical R&D center at premises of the state enterprise Academpharm. The Indian company will invest $1 million in the project initially. The project’s implementation was discussed during the meeting with Mikhail Myasnikovich. The head of the upper chamber of the Belarusian parliament noted that cooperation between Academpharm and Cipla Limited goes beyond making money. “I am talking about scientific and innovative cooperation. Because Academpharm and Cipla Limited have a joint innovative interest: science, experimental development, mass production,” said Mikhail Myasnikovich. “It is top class when a joint venture is established to make cutting-edge patented medications.” Mikhail Myasnikovich also underlined the high level of Belarusian science. The interest world companies show in Belarusian science confirms it.

A pharmaceutical enterprise will be established at Academpharm premises to make medications to treat HIV infection, hepatitis B and C among other things. The Indian company will provide modern technologies and techniques for the sake of the project’s implementation: micronization, dry granulation, and multilayered pills. The R&D center is expected to manufacture medications using a complete cycle – from a scientific idea to manufacturing. The facility is supposed to open in spring 2020.

Founded in 1935, Cipla Limited is focused on development, chemical synthesis, and production of over 1,500 ready-made medications. It offers antitumor medications, bronchodilators, corticosteroids, immunosuppressants, chemotherapeutic and antiretroviral agents, antibiotics, and antidepressants. Cipla Limited is present in 150 countries across the globe.